Advanced

Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2

Kleef, Ralf; Moss, Ralph; Szasz, A. Marcell LU ; Bohdjalian, Arthur; Bojar, Hans and Bakacs, Tibor (2018) In Integrative cancer therapies 17(4). p.1297-1303
Abstract

The prognosis of triple-negative breast cancer with metastases after chemotherapy remains dismal. We report the case of a 50-year-old female with first disease recurrence at the axillary lymph node and, later on, bilateral pulmonary metastases with severe shortness of breath. The patient received low-dose immune checkpoint blockade (concurrent nivolumab and ipilimumab) weekly over 3 weeks with regional hyperthermia 3 times a week, followed by systemic fever-range hyperthermia induced by interleukin-2 for 5 days. She went into complete remission of her pulmonary metastases with transient WHO I-II diarrhea and skin rash. The patient remained alive for 27 months after the start of treatment, with recurrence of metastases as a sternal mass,... (More)

The prognosis of triple-negative breast cancer with metastases after chemotherapy remains dismal. We report the case of a 50-year-old female with first disease recurrence at the axillary lymph node and, later on, bilateral pulmonary metastases with severe shortness of breath. The patient received low-dose immune checkpoint blockade (concurrent nivolumab and ipilimumab) weekly over 3 weeks with regional hyperthermia 3 times a week, followed by systemic fever-range hyperthermia induced by interleukin-2 for 5 days. She went into complete remission of her pulmonary metastases with transient WHO I-II diarrhea and skin rash. The patient remained alive for 27 months after the start of treatment, with recurrence of metastases as a sternal mass, and up to 3 cm pleural metastases. This exceptional response should instigate further research efforts with this protocol, which consists only of approved drugs and treatments.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
checkpoint inhibition, hyperthermia, IL-2, immunotherapy, TNBC
in
Integrative cancer therapies
volume
17
issue
4
pages
7 pages
external identifiers
  • scopus:85056277167
DOI
10.1177/1534735418794867
language
English
LU publication?
yes
id
7b2b5422-14a1-433e-b133-713a1dbd3aac
date added to LUP
2018-11-21 12:56:30
date last changed
2019-01-06 14:16:29
@article{7b2b5422-14a1-433e-b133-713a1dbd3aac,
  abstract     = {<p>The prognosis of triple-negative breast cancer with metastases after chemotherapy remains dismal. We report the case of a 50-year-old female with first disease recurrence at the axillary lymph node and, later on, bilateral pulmonary metastases with severe shortness of breath. The patient received low-dose immune checkpoint blockade (concurrent nivolumab and ipilimumab) weekly over 3 weeks with regional hyperthermia 3 times a week, followed by systemic fever-range hyperthermia induced by interleukin-2 for 5 days. She went into complete remission of her pulmonary metastases with transient WHO I-II diarrhea and skin rash. The patient remained alive for 27 months after the start of treatment, with recurrence of metastases as a sternal mass, and up to 3 cm pleural metastases. This exceptional response should instigate further research efforts with this protocol, which consists only of approved drugs and treatments.</p>},
  author       = {Kleef, Ralf and Moss, Ralph and Szasz, A. Marcell and Bohdjalian, Arthur and Bojar, Hans and Bakacs, Tibor},
  keyword      = {checkpoint inhibition,hyperthermia,IL-2,immunotherapy,TNBC},
  language     = {eng},
  number       = {4},
  pages        = {1297--1303},
  series       = {Integrative cancer therapies},
  title        = {Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2},
  url          = {http://dx.doi.org/10.1177/1534735418794867},
  volume       = {17},
  year         = {2018},
}